You are here:

dolutegravir, abacavir, lamivudine (Triumeq)

Advice

following an abbreviated submission:

dolutegravir, abacavir plus lamivudine tablets (Triumeq®) are accepted for use within NHS Scotland.

Indication under review: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of (Triumeq®). This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

 

Drug Details

Drug Name: dolutegravir, abacavir, lamivudine (Triumeq)
SMC Drug ID: 1009/14
Manufacturer: ViiV Healthcare/GSK
Indication: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 December 2014

Back